Multicenter trial of olmesartan. Main results

Multicenter trial of olmesartan. Main results

Development and introduction into practice of medicines reducing activity of the renin-angiotensin-aldosteron system the key element of which is angiotensin II (ATII) resulted in a significant improvement of efficacy of cardiovascular diseases treatment. Angiotensin converting enzyme (ACE) inhibitor...

Full description

Bibliographic Details
Main Authors:	Fail' Taipovich Ageev, Ol'ga Nikolaevna Svirida, F T Ageev, O N Svirida
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2011-09-01
Series:	Терапевтический архив
Subjects:	olmesartan angiotensin ii receptor blocker arterial pressure diabetes mellitus organ protection
Online Access:	https://ter-arkhiv.ru/0040-3660/article/view/30927

Similar Items

Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
by: Mason
Published: (2011-06-01)

EFFECT OF ANGIOTENSIN RECEPTOR BLOCKADE ON ENDOTHELIAL FUNCTION: FOCUS ON OLMESARTAN MEDOXOMIL
by: C. Ferrario
Published: (2010-12-01)

LONG-TERM EFFECTS OF OLMESARTAN, AN ANG II RECEPTOR ANTAGONIST, ON BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
by: Shuichi Ichikawa, et al.
Published: (2011-06-01)

Olmesartan in Management of Proteinuria
by: Satyanarayan Routray, et al.
Published: (2018-02-01)

Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study
by: Nakayama Tomohiro, et al.
Published: (2011-08-01)

Effects of telmisartan and olmesartan on insulin sensitivity and renal function in spontaneously hypertensive rats fed a high fat diet
by: Hayato Yanagihara, et al.
Published: (2016-07-01)

Olmesartan Attenuates Single-Lung Ventilation Induced Lung Injury via Regulating Pulmonary Microbiota
by: Di Lu, et al.
Published: (2022-03-01)

Tratamento da hipertensão arterial com olmesartana medoxomila em escalonamento Based treatment algorithm for essencial hypertension with olmesartan medoxomil
by: Marco Antônio Mota Gomes, et al.
Published: (2008-09-01)

Olmesartan: vasoprotective effects and reducing the risk of vascular accidents
by: O. D. Ostroumova, et al.
Published: (2014-12-01)

Olmesartan Reduces New-onset Atrial Fibrillation and Atrial Fibrillation Burden after Dual-chamber Pacemaker Implantation in Atrioventricular Block Patients
by: Hang Zhang, et al.
Published: (2016-01-01)

Enteropatía por olmesartán
Published: (2017-12-01)

Olmesartan-induced enteropathy
by: Sofia Moura de Azevedo, et al.
Published: (2023-01-01)

ARB I olmesartan interruption in cardiovascular and cardiorenal continuum: antihypertensive and nephroprotective effects (part 1)
by: M. G Bubnova
Published: (2014-12-01)

Effect of olmesartan and amlodipine on serum angiotensin-(1–7) levels and kidney and vascular function in patients with type 2 diabetes and hypertension
by: Kyuho Kim, et al.
Published: (2023-03-01)

BLOOD PRESSURE-LOWERING EFFICACY OF OLMESARTAN RELATIVE TO OTHER ANGIOTENSIN II RECEPTOR ANTAGONISTS: AN OVERVIEW OF RANDOMIZED CONTROLLED STUDIES
by: Faiez Zannad, et al.
Published: (2010-08-01)

Olmesartan-Associated Enteropathy: An Unexpected Cause of Chronic Diarrhoea
by: Mónica Martins Teixeira, et al.
Published: (2019-04-01)

Different chronotherapeutic effects of valsartan and olmesartan in non-dipper hypertensive patients during valsartan treatment at morning
by: Kentaro Ushijima, et al.
Published: (2015-01-01)

Efficacy and safety of a combination antihypertensive drug (olmesartan plus azelnidipine): “Issues with hypertension studies in real-world practice”
by: Keisuke Okamura, et al.
Published: (2020-07-01)

TELMISARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION. CASE STUDY
by: V. I. Podzolkov, et al.
Published: (2015-12-01)

Olmesartan/amlodipine: a review of its use in the management of hypertension
by: Kreutz R
Published: (2011-03-01)

Blocker, angiotensin II receptor olmesartan to interrupt cardiovascular continuum: vesselsand cardioprotective, anti-atherosclerotic and metabolic pleiotropic effects (part 2)
by: M. G Bubnova
Published: (2015-03-01)

Olmesartan: A Little-Known Cause of Diarrhoea
by: Joana Serôdio, et al.
Published: (2019-06-01)

Enteropatía asociada a Olmesartan
by: Virginia González Hidalgo, et al.
Published: (2021-04-01)

Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer
by: Hiroji Uemura, et al.
Published: (2011-12-01)

Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer
by: Hiroji Uemura, et al.
Published: (2011-12-01)

Effect of Probenecid on Pharmacokinetics and Tolerability of Olmesartan in Healthy Chinese Volunteers
by: Kun-Yan Li, PhD, et al.
Published: (2014-12-01)

Efficacy of olmesartan amlodipine in Colombian hypertensive patients (soat study)
by: Richard Buendia, et al.
Published: (2017-04-01)

Combination Therapy with Olmesartan and Amlodipine in the Treatment of Hypertension
by: Menco G. Niemeijer, et al.
Published: (2009-12-01)

Comparison of effects between calcium channel blocker and diuretics in combination with angiotensin II receptor blocker on 24-h central blood pressure and vascular hemodynamic parameters in hypertensive patients: study design for a multicenter, double-blinded, active-controlled, phase 4, randomized trial
by: Gyu Chul Oh, et al.
Published: (2017-09-01)

A comparative study on the pleiotropic effects of Olmesartan and Telmisartan in hypertensive patients with type 2 diabetes mellitus: A randomized, prospective, open labelled, hospital based study
by: Vineela Karthik N, et al.
Published: (2023-07-01)

Olmesartan-Induced Enteropathy: A Case of Recurrent Diarrhoea
by: Ana Rita Matos, et al.
Published: (2020-05-01)

Severe spruelike enteropathy due to olmesartan
by: Gioia Fiorucci, et al.
Published: (2014-02-01)

Stability-indicating comparative methods using mekc and lc for determination of olmesartan medoxomil
by: Lisiane Bajerski, et al.
Published: (2013-01-01)

Stability-indicating comparative methods using mekc and lc for determination of olmesartan medoxomil
by: Lisiane Bajerski, et al.
Published: (2013-01-01)

The Effect of an Angiotensin Receptor Blocker on Arterial Stiffness in Type 2 Diabetes Mellitus Patients with Hypertension
by: Ji Hyun Kim, et al.
Published: (2011-06-01)

PHARMACOECONOMIC ANALYSIS OF OLMESARTAN THERAPY IN THE INDIVIDUAL–LEVEL MANAGEMENT OF ARTERIAL HYPERTENSION
by: S. G. Gorokhova, et al.
Published: (2012-08-01)

Olmesartan-associated Enteropathy with Acute Kidney Injury
by: Moo Jin Kang, et al.
Published: (2022-03-01)

Sartans in cardiological practice: new possibilities in therapy of cardiovascular diseases
by: O G Smolenskaya
Published: (2009-06-01)

Vasorelaxant Effect of a Newly Synthesized Dihydropyridine Ethyl Ester (DHPEE) on Rat Thoracic Aorta: Dual Mechanism of Action
by: Hossein Babaei, et al.
Published: (2011-06-01)

Cardiometabolic properties of telmisartan: new perspectives for use
by: O. M. Drapkina, et al.
Published: (2015-12-01)